Improvement in cardiac energetics by perhexiline in heart failure due to dilated cardiomyopathy

JACC: Heart Failure

Volumn 3, Issue 3, 2015, Pages 202-211

  Beadle, Roger M ^a   Williams, Lynne K ^b   Kuehl, Michael ^c   Bowater, Sarah ^c   Abozguia, Khalid ^c   Leyva, Francisco ^c   Yousef, Zaheer ^d   Wagenmakers, Anton J M ^e   Thies, Frank ^a   Horowitz, John ^f   Frenneaux, Michael P ^a  

^a UNIVERSITY OF ABERDEEN   (United Kingdom)

^b TORONTO GENERAL HOSPITAL   (Canada)

^c UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^d UNIVERSITY HOSPITAL OF WALES   (United Kingdom)

^e LIVERPOOL JOHN MOORES UNIVERSITY   (United Kingdom)

^f QUEEN ELIZABETH HOSPITAL   (Australia)

Author keywords

Heart failure; Magnetic resonance spectroscopy; Myocardial metabolism; Perhexiline

Indexed keywords

ADENOSINE TRIPHOSPHATE; AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CREATINE PHOSPHATE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; FATTY ACID; MINERALOCORTICOID ANTAGONIST; PERHEXILINE; PLACEBO; CARDIOVASCULAR AGENT;

ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL ASSESSMENT; CONGESTIVE CARDIOMYOPATHY; CONTROLLED STUDY; DIARRHEA; DIASTOLIC BLOOD PRESSURE; DISEASE SEVERITY; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; ECHOCARDIOGRAPHY; ENZYME LINKED IMMUNOSORBENT ASSAY; EXERCISE; FEMALE; HEART FAILURE; HEART FUNCTION; HEART LEFT VENTRICLE EJECTION FRACTION; HUMAN; LUNG GAS EXCHANGE; MALE; NAUSEA; PHOSPHATE METABOLISM; PHOSPHORUS NUCLEAR MAGNETIC RESONANCE; PRIORITY JOURNAL; QUALITY OF LIFE; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL; SYSTOLIC BLOOD PRESSURE; TREATMENT DURATION; TREATMENT RESPONSE; CARDIOMYOPATHY, DILATED; CLINICAL TRIAL; COMPLICATION; DRUG EFFECTS; ENERGY METABOLISM; FOLLOW UP; HEART LEFT VENTRICLE FUNCTION; HEART MUSCLE; HEART STROKE VOLUME; METABOLISM; MIDDLE AGED; MULTICENTER STUDY; PATHOPHYSIOLOGY; RETROSPECTIVE STUDY; TIME; TREATMENT OUTCOME;

CARDIOMYOPATHY, DILATED; CARDIOVASCULAR AGENTS; DOUBLE-BLIND METHOD; ECHOCARDIOGRAPHY; ENERGY METABOLISM; FEMALE; FOLLOW-UP STUDIES; HEART FAILURE; HUMANS; MALE; MIDDLE AGED; MYOCARDIUM; PERHEXILINE; RETROSPECTIVE STUDIES; STROKE VOLUME; TIME FACTORS; TREATMENT OUTCOME; VENTRICULAR FUNCTION, LEFT;

EID: 84924984745     PISSN: 22131779     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jchf.2014.09.009     Document Type: Article

References (26)

1. Stewart S., MacIntyre K., Hole D.J., Capewell S., McMurray J.J. More 'malignant' than cancer? Five-year survival following a first admission forheart failure. Eur J Heart Fail 2001, 3:315-322.
2. Rich M.W., Beckham V., Wittenberg C., Leven C.L., Freedland K.E., Carney R.M. Amultidisciplinary intervention to prevent the readmission of elderly patients with congestive heart failure. NEngl J Med 1995, 333:1190-1195.
3. Neubauer S. The failing heart-an engine out of fuel. NEngl J Med 2007, 356:1140-1151.
4. Cole P.L., Beamer A.D., McGowan N., et al. Efficacy and safety of perhexiline maleate in refractory angina. A double-blind placebo-controlled clinical trial of a novel antianginal agent. Circulation 1990, 81:1260-1270.
5. Lee L., Campbell R., Scheuermann-Freestone M., et al. Metabolic modulation with perhexiline in chronic heart failure: a randomized, controlled trial of short-term use of a novel treatment. Circulation 2005, 112:3280-3288.
6. Abozguia K., Elliott P., McKenna W., et al. Metabolic modulator perhexiline corrects energy deficiency and improves exercise capacity in symptomatic hypertrophic cardiomyopathy. Circulation 2010, 122:1562-1569.
7. Horowitz J.D., Sia S.T., Macdonald P.S., Goble A.J., Louis W.J. Perhexiline maleate treatment for severe angina pectoris-correlations with pharmacokinetics. Int J Cardiol 1986, 13:219-229.
8. Kennedy J.A., Unger S.A., Horowitz J.D. Inhibition of carnitine palmitoyltransferase-1 in rat heart and liver by perhexiline and amiodarone. Biochem Pharmacol 1996, 52:273-280.
9. Bottomley P.A., Weiss R.G. Non-invasive magnetic-resonance detection of creatine depletion in non-viable infarcted myocardium. Lancet 1998, 351:714-718.
10. Conway M.A., Allis J., Ouwerkerk R., Niioka T., Rajagopalan B., Radda G.K. Detection of low phosphocreatine to ATP ratio in failing hypertrophied human myocardium by 31P magnetic resonance spectroscopy. Lancet 1991, 338:973-976.
11. Birks E.J. Molecular changes after left ventricular assist device support for heart failure. Circ Res 2013, 113:777-791.
12. Hugel S., Horn M., de Groot M., et al. EffectsofACE inhibition and beta-receptor blockade on energy metabolism in rats postmyocardial infarction. Am J Physiol 1999, 277:H2167-H2175.
13. Sanbe A., Tanonaka K., Kobayasi R., Takeo S. Effects of long-term therapy with ACE inhibitors, captopril, enalapril and trandolapril, on myocardial energy metabolism in rats with heart failure following myocardial infarction. JMol Cell Cardiol 1995, 27:2209-2222.
14. Beadle R.M., Williams L.K., Abozguia K., et al. Metabolic manipulation in chronic heart failure: study protocol for a randomised controlled trial. Trials 2011, 12:140.
15. Hughes D., Talwar S., Squire I.B., Davies J.E., Ng L.L. An immunoluminometric assay for N-terminalpro-brain natriuretic peptide: development of a test for left ventricular dysfunction. Clin Sci (Lond) 1999, 96:373-380.
16. Conway M.A., Bottomley P.A., Ouwerkerk R., Radda G.K., Rajagopalan B. Mitral regurgitation: impaired systolic function, eccentric hypertrophy, and increased severity are linked to lower phosphocreatine/ATP ratios in humans. Circulation 1998, 97:1716-1723.
17. Cavassila S., Deval S., Huegen C., van O.D., Graveron-Demilly D. Cramer-Rao bounds: an evaluation tool for quantitation. NMR Biomed 2001, 14:278-283.
18. Thackray S.D., Witte K.K., Nikitin N.P., Clark A.L., Kaye G.C., Cleland J.G. The prevalence of heart failure and asymptomatic left ventricular systolic dysfunction in a typical regional pacemaker population. Eur Heart J 2003, 24:1143-1152.
19. Schiller N.B., Shah P.M., Crawford M., et al. Recommendations for quantitation of the left ventricle by two-dimensional echocardiography. American Society of Echocardiography Committee on Standards, Subcommittee on Quantitation ofTwo-Dimensional Echocardiograms. JAm Soc Echocardiogr 1989, 2:358-367.
20. Shivu G.N., Abozguia K., Phan T.T., Ahmed I., Henning A., Frenneaux M. (31)P magnetic resonancespectroscopy to measure invivo cardiac energetics in normal myocardium and hypertrophic cardiomyopathy: experiences at 3T. Eur J Radiol 2010, 73:255-259.
21. Unger S.A., Kennedy J.A., Fadden-Lewis K., Minerds K., Murphy G.A., Horowitz J.D. Dissociationbetween metabolic and efficiency effects of perhexiline in normoxic rat myocardium. JCardiovasc Pharmacol 2005, 46:849-855.
22. Gatto G.J., Ao Z., Kearse M.G., et al. NADPH oxidase-dependent and -independent mechanisms of reported inhibitors of reactive oxygen generation. JEnzyme Inhib Med Chem 2013, 28:95-104.
23. Balgi A.D., Fonseca B.D., Donohue E., et al. Screen for chemical modulators of autophagy reveals novel therapeutic inhibitors of mTORC1 signaling. PLoS One 2009, 4:e7124.
24. Dedkova E.N., Seidlmayer L.K., Blatter L.A. Mitochondria-mediated cardioprotection by trimetazidine in rabbit heart failure. JMol Cell Cardiol 2013, 59:41-54.
25. Gao D., Ning N., Niu X., Hao G., Meng Z. Trimetazidine: a meta-analysis of randomised controlled trials in heart failure. Heart 2011, 97:278-286.
26. Fragasso G., Perseghin G., De Cobelli F., et al. Effects of metabolic modulation by trimetazidine on left ventricular function and phosphocreatine/adenosine triphosphate ratio in patients with heart failure. Eur Heart J 2006, 27:942-948.